Search Results 1771-1780 of 18816 for Relapse
... Relapsed or Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL). Rochester ... Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL). A Blood ...
The purpose of this study is to assess the safety and tolerability of escalating intratumoral doses of mRNA-2752 in participants with relapsed/refractory solid ...
Also, to improve disease control by decreasing the number of spinal relapses for patients who achieve a complete response (CR) or partial response (PR) and ...
Patients at high risk of relapse are eligible for InPACT-pelvis, where they are randomised to either: P. prophylactic PLND Q. no prophylactic PLND. Rare ...
Patients at high risk of relapse are eligible for InPACT-pelvis, where they ... A Study to Evaluate VSV-hIFNbeta-NIS to Treat Patients with Relapsed/Refractory ...
... relapsed after or is refractory to prior therapies, including proteasome inhibitors (PIs), immunomodulators (IMiDs) and anti-CD38 targeted therapies ...
To prevent relapses, Mayo Clinic uses steroid-sparing immunosuppressants. "We find that patients often can be weaned off immunotherapy after 2 to 5 years ...
Patients must have relapsed or become refractory to conventional therapy, with a regimen including some combination of high dose methotrexate, doxorubicin ...
Relapsed or refractory to hypomethylating agents; Acute myeloid leukemia (AML), except those patients with RAEB-t who are not candidates for intensive AML ...
Mayo Clinic does not endorse companies or products. Advertising revenue supports our not-for-profit mission.
Check out these best-sellers and special offers on books and newsletters from Mayo Clinic Press.
Your donation powers the future of medicine and helps save lives.